[17] – 1995 (4/26/1995) (Pg. 3)

This page is linked to:
Critiquing: Dr. Michael A. Friedman, Dr. Mark G. Malkin, Dr. Mario Sznol, Robert B. Lanman, Memorial Sloan-Kettering Cancer Center, Mayo Clinic, Department of Health & Human Services (HHS), Public Health Service, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Center (NCI) at the National Institutes of Health (NIH), Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies
[17] – 1995 (4/26/1995) (Pg. 3)
Without Dr. Burzynski’s knowledge or permission, Memorial Sloan-Kettering Cancer Center recently amended the protocol for testing antineoplastons in adult patients with advanced brain tumors

Previously, by agreement with the developer, only patients whose brain tumors were no bigger than 5 centimeters (cm) in diameter were accepted into the antineoplaston program at MSKCC

Now MSKCC, NCI, and FDA have agreed among themselves to accept patients with any tumors, including those larger than 5 cm, as well as with multiple tumors, distant metastases, and lower Karnofsky (performance) scores

If the treatment fails, then this will probably be chalked up against antineoplastons and non-toxic treatments in general

Yet at the dosage levels and with the combinations of drugs stipulated in the original protocol, in Burzynski’s view, the treatment almost certainly will fail

All parties are aware of this fact

The rationale given for this change is that with wider criteria more patients can


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s